Long-term follow-up for childhood cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to track and collect follow-up information from patients who have participated in Children's Oncology Group studies. It focuses on maintaining lifetime contact with these patients to gather updates on their health status and quality of life. The study also seeks to locate patients who have become lost to follow-up and provide their current information to relevant institutions. By developing a systematic approach to long-term follow-up, the study hopes to enhance understanding of the long-term effects of cancer treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient must reside in the U.S. on the date of enrollment to ALTE05N1
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Where it's running

• Children's Hospital of Alabama
  Birmingham, Alabama, United States Recruiting
• USA Health Strada Patient Care Center
  Mobile, Alabama, United States Recruiting
• Phoenix Childrens Hospital
  Phoenix, Arizona, United States Recruiting
• The University of Arizona Medical Center-University Campus
  Tucson, Arizona, United States Recruiting
• Arkansas Children's Hospital
  Little Rock, Arkansas, United States Recruiting
• Kaiser Permanente Downey Medical Center
  Downey, California, United States Recruiting

+114 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Smita Bhatia — Children's Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Molecular profiling for treating pediatric and young adult cancers

  This study is testing if using genetic information from tumors can help doctors find better treatments for kids and young adults with hard-to-treat cancers.

  Recruiting at 29 sites Gustave Roussy, Cancer Campus, Grand Paris · Amiens, France and 28 other locations · NCT05691608

• A network for collaborative cancer research in Ontario

  This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.

  Recruiting at 2 sites University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT05403177

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.